Dow Expands Capacity for Polyethlene Glycols
The company’s planned investment in its alkoxylation facility in the United States Gulf Coast will also expand production capacity for its polyethylene glycols.
The Dow Chemical Company announced on Oct. 10, 2018, that its planned alkoxylation facility investment on the United States Gulf Coast will expand production capacity for polyethylene glycols (PEGs), among other diverse products. PEGs are used as excipients in pharmaceutical manufacturing. The capacity expansion will enable the company to meet growing market demand for Carbowax Sentry PEGs in solid (powder and granular) form.
“As an industry-leading global provider of polyethylene glycols, we’re dedicated to reliably supplying this market to support our current and future customers in this space,” said Ester Baiget, business president for Dow Industrial Solutions, in a company press release. “Our Carbowax Sentry PEGs brand has decades of proven performance in helping customers adhere to strict regulatory and formulation requirements, and this capacity expansion allows us to continue meeting their need for high-quality PEGs for many decades to come.”
The new alkoxylation facility, which was announced in June 2018, is scheduled to come online in 2021 and will reinforce Dow’s position in polyethylene glycols. To further expand its efforts to increase production capacity, the company is currently undergoing debottlenecking across its alkoxylation production units globally.
Source: The Dow Chemical Company
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
